Pharming Group N.V. (PHAR)

Pharming Group Balance Sheet

Financials in millions EUR. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019	2018
Cash & Equivalents	61.74	207.56	192.15	206.15	74.35	80.31
Short-Term Investments	151.68	0	0	0	0	0
Cash & Cash Equivalents	213.42	207.56	192.15	206.15	74.35	80.31
Cash Growth	2.83%	8.02%	-6.79%	177.28%	-7.42%	-
Receivables	46.16	27.62	29.98	35.9	28.86	17.81
Inventory	56.76	42.33	27.31	21.16	16.22	17.32
Total Current Assets	316.34	277.5	249.44	263.21	119.44	115.44
Property, Plant & Equipment	33.47	39.15	33.17	21.65	16.3	8.4
Long-Term Investments	11.93	10.83	9.46	7.63	8.72	1.2
Goodwill and Intangibles	71.27	75.12	83.83	94.08	79.4	52.44
Other Long-Term Assets	29.85	23.2	21.41	31.88	32.06	37
Total Long-Term Assets	146.51	148.3	147.87	155.24	136.48	99.04
Total Assets	462.85	425.8	397.32	418.45	255.92	214.48
Accounts Payable	72.53	54.47	42.47	47.67	40.65	28.59
Deferred Revenue	0	0	0	0	0	1.47
Current Debt	5.44	5.23	4.3	29	73.31	52.98
Other Current Liabilities	0	0	0	0.18	0.3	-0.44
Total Current Liabilities	77.97	59.7	46.77	76.85	114.25	82.6
Long-Term Debt	166.11	161.46	157.63	158.17	24.27	69.47
Other Long-Term Liabilities	0	0	0	0	0	0.67
Total Long-Term Liabilities	166.11	161.46	157.63	158.17	24.27	70.13
Total Liabilities	244.07	221.16	204.4	235.02	138.53	152.73
Total Debt	171.55	166.69	161.93	187.17	97.58	122.45
Debt Growth	2.91%	2.94%	-13.49%	91.81%	-20.31%	-
Retained Earnings	-265.26	-256.43	-273.17	-295.62	-340.72	-333.64
Shareholders' Equity	218.78	204.64	192.92	183.44	117.39	61.75
Net Cash / Debt	41.88	40.86	30.23	18.98	-23.23	-42.14
Net Cash / Debt Growth	2.49%	35.19%	59.22%	-	-	-
Working Capital	238.37	217.8	202.67	186.36	5.18	32.84
Book Value Per Share	3.32	3.15	3.02	2.88	1.84	-

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).